Prestige Consumer Healthcare Inc. (PBH) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024 (Q2 of Fiscal Year 2025). Prestige Consumer Healthcare Inc. develops, manufactures, and markets over-the-counter (OTC) healthcare products in North America and international markets. The company operates two reportable segments: North American OTC Healthcare and International OTC Healthcare.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $283.8 million | $286.3 million | $550.9 million | $565.6 million |
| Gross Profit | $157.4 million | $160.0 million | $303.4 million | $314.7 million |
| Gross Margin | 55.5% | 55.9% | 55.1% | 55.6% |
| Operating Income | $84.3 million | $88.3 million | $156.4 million | $173.4 million |
| Net Income | $54.4 million | $53.6 million | $103.4 million | $106.8 million |
| Diluted EPS | $1.09 | $1.07 | $2.06 | $2.13 |
| Operating Cash Flow (YTD) | $124.6 million (vs. $110.5 million YTD 2023) | |||
| Long-Term Debt (Net) | $1.052 billion (as of Sept 30, 2024) | |||
| Cash & Equivalents | $51.5 million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 0.9% in Q2 and 2.6% YTD compared to the prior year. The North American segment declined 1.9% in Q2 and 3.8% YTD, driven by lower sales in Eye & Ear Care, Cough & Cold, and Analgesics categories. This was partially offset by growth in the Gastrointestinal category.
- International Growth: The International segment saw revenue increases of 5.0% in both Q2 and YTD, primarily due to strong performance in the Gastrointestinal category.
- Margin Compression: Gross margins decreased slightly (55.5% in Q2 vs. 55.9% prior year) due to revenue declines and increased supply chain costs, partially offset by pricing actions.
- Interest Expense Reduction: Net interest expense dropped significantly to $12.3 million in Q2 (from $17.6 million) and $25.4 million YTD (from $35.3 million) due to reduced average indebtedness and lower borrowing costs.
- Share Repurchases: The company repurchased $11.8 million of stock in Q2 and $37.8 million YTD under a $300 million authorization approved in May 2024.
Outlook, Risks, and Management Commentary
- Supply Chain Challenges: Management cites ongoing economic uncertainty, inflation, and supply chain constraints. Specific shortages in eye care products have negatively impacted sales, with expectations that further shortages may continue to affect results.
- Cost Pressures: Rising input costs for raw materials, labor, and shipping continue to pressure margins. The company notes a shift in consumer purchasing patterns toward online channels.
- Debt Management: The company reduced its Term B-5 Loan balance by $75 million YTD. It maintains a leverage ratio of less than 6.50:1 and is in compliance with all financial covenants.
- Tax Rate: The effective tax rate for the six months ended September 30, 2024, was 20.5%, down from 23.2% in the prior year, largely due to the release of a reserve for uncertain tax positions.
- Subsequent Event: On October 1, 2024, the company extended its logistics agreement with GEODIS Logistics LLC for an additional 65 months.
Investor Verification Checklist
- Verify the extent of ongoing inventory shortages, specifically in the Eye & Ear Care category, and their projected impact on Q3 and Q4 sales.
- Monitor the effectiveness of pricing actions in offsetting rising supply chain and input costs to protect gross margins.
- Review the concentration risk associated with top customers (Walmart ~19-20% and Amazon ~12-13% of revenue) and key third-party manufacturers (one supplier accounts for ~22% of revenue).
- Assess the sustainability of the reduced interest expense given the company's remaining $1.06 billion debt load and variable rate exposure on the Term B-5 Loan.
- Track the execution of the $300 million share repurchase program and its impact on diluted EPS.